0.54 USD
-0.07 (-12.01%)
0.55 USD
+0.01 (+1.85%)
We assign a fundamental rating of 3 out of 10 to NXL. NXL was compared to 186 industry peers in the Health Care Equipment & Supplies industry. While NXL has a great health rating, there are worries on its profitability. NXL is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NXL had negative earnings in the past year.
In the past year NXL has reported a negative cash flow from operations.
In the past 5 years NXL always reported negative net income.
In the past 5 years NXL always reported negative operating cash flow.
1.2 Ratios
NXL's Return On Assets of -169.31% is on the low side compared to the rest of the industry. NXL is outperformed by 89.78% of its industry peers.
Looking at the Return On Equity, with a value of -182.01%, NXL is doing worse than 70.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -169.31% | ||
| ROE | -182.01% | ||
| ROIC | N/A |
ROA(3y)-110.33%
ROA(5y)-801.91%
ROE(3y)-127.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 69.55%, NXL is in the better half of the industry, outperforming 76.88% of the companies in the same industry.
In the last couple of years the Gross Margin of NXL has grown nicely.
The Profit Margin and Operating Margin are not available for NXL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.55% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.73%
GM growth 5Y2.21%
2. Health
2.1 Basic Checks
NXL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NXL has been increased compared to 1 year ago.
Compared to 5 years ago, NXL has more shares outstanding
There is no outstanding debt for NXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -10.13, we must say that NXL is in the distress zone and has some risk of bankruptcy.
NXL has a worse Altman-Z score (-10.13) than 80.11% of its industry peers.
There is no outstanding debt for NXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.13 |
ROIC/WACCN/A
WACC8.76%
2.3 Liquidity
A Current Ratio of 13.48 indicates that NXL has no problem at all paying its short term obligations.
NXL has a better Current ratio (13.48) than 97.31% of its industry peers.
A Quick Ratio of 13.03 indicates that NXL has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 13.03, NXL belongs to the best of the industry, outperforming 97.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.48 | ||
| Quick Ratio | 13.03 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 0.33% over the past year.
The Revenue has decreased by -3.09% in the past year.
NXL shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.05% yearly.
EPS 1Y (TTM)0.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.48%
Revenue 1Y (TTM)-3.09%
Revenue growth 3Y5.39%
Revenue growth 5Y-4.05%
Sales Q2Q%-49.58%
3.2 Future
NXL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.65% yearly.
Based on estimates for the next years, NXL will show a very strong growth in Revenue. The Revenue will grow by 95.89% on average per year.
EPS Next Y19.67%
EPS Next 2Y16.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year34.3%
Revenue Next 2Y95.89%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NXL. In the last year negative earnings were reported.
Also next year NXL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NXL's earnings are expected to grow with 16.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.65%
EPS Next 3YN/A
5. Dividend
5.1 Amount
NXL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
0.54
-0.07 (-12.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners3.78%
Inst Owner Change-46.37%
Ins Owners12.78%
Ins Owner Change5.82%
Market Cap10.07M
Revenue(TTM)157.00K
Net Income(TTM)-8.68M
Analysts80
Price Target4.08 (655.56%)
Short Float %0.32%
Short Ratio0.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.01%
Min EPS beat(2)-7.26%
Max EPS beat(2)29.28%
EPS beat(4)1
Avg EPS beat(4)-39.38%
Min EPS beat(4)-131.02%
Max EPS beat(4)29.28%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)21.47%
Min Revenue beat(2)-55.07%
Max Revenue beat(2)98.02%
Revenue beat(4)2
Avg Revenue beat(4)12.01%
Min Revenue beat(4)-55.07%
Max Revenue beat(4)98.02%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 64.15 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.11 | ||
| P/tB | 2.26 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.66
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.01
BVpS0.26
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -169.31% | ||
| ROE | -182.01% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.55% | ||
| FCFM | N/A |
ROA(3y)-110.33%
ROA(5y)-801.91%
ROE(3y)-127.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.73%
GM growth 5Y2.21%
F-Score2
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 92.42% | ||
| Cap/Sales | 11.66% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 13.48 | ||
| Quick Ratio | 13.03 | ||
| Altman-Z | -10.13 |
F-Score2
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.48%
EPS Next Y19.67%
EPS Next 2Y16.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-3.09%
Revenue growth 3Y5.39%
Revenue growth 5Y-4.05%
Sales Q2Q%-49.58%
Revenue Next Year34.3%
Revenue Next 2Y95.89%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-36.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.27%
OCF growth 3YN/A
OCF growth 5YN/A
NEXALIN TECHNOLOGY INC / NXL FAQ
Can you provide the ChartMill fundamental rating for NEXALIN TECHNOLOGY INC?
ChartMill assigns a fundamental rating of 3 / 10 to NXL.
What is the valuation status of NEXALIN TECHNOLOGY INC (NXL) stock?
ChartMill assigns a valuation rating of 0 / 10 to NEXALIN TECHNOLOGY INC (NXL). This can be considered as Overvalued.
How profitable is NEXALIN TECHNOLOGY INC (NXL) stock?
NEXALIN TECHNOLOGY INC (NXL) has a profitability rating of 1 / 10.
What is the financial health of NEXALIN TECHNOLOGY INC (NXL) stock?
The financial health rating of NEXALIN TECHNOLOGY INC (NXL) is 7 / 10.